Georgia Capital 3Q23 & 9M23 Performance Overview

DELEVERAGING ACROSS OUR PRIVATE PORTFOLIO AGGREGATED LEVERAGE ACROSS OUR PRIVATE LARGE AND INVESTMENT STAGE PORTFOLIO COMPANIES AT 3.1x AS OF 30-SEP-23 ADJUSTED NET DEBT/EBITDA 30-JUN-23 CHANGE 30-SEP-23 GEORGIA CAPITAL TARGET (OVER THE CYCLE) LARGE PORTFOLIO COMPANIES Retail (pharmacy)¹ 1.7x +0.6x 2.3x Up to 1.5x Hospitals 4.1x +0.2x 4.3x Up to 2.5x Insurance (P&C and Medical) No leverage NMF No leverage No leverage INVESTMENT STAGE PORTFOLIO COMPANIES Renewable Energy² 7.1x -0.1x 7.0x Up to 6.0x Education 1.0x +0.3x 1.3x Up to 2.5x Clinics and Diagnostics 7.1x -2.4x 4.7x3 Up to 2.5x Georgia Capital PLC | General note: Figures for Hospitals, Retail (Pharmacy), Clinics and Diagnostics are given excluding IFRS 16 effects; Net debt/EBITDA is adjusted for capital commitments. 1. Includes the application of the minority buyout agreement. 2. Renewable energy ratio is calculated in US$. 3. LTM EBITDA excludes the gain of GEL 2.9 million from the sale of one of the polyclinics buildings in 3Q23. The net debt includes the receivable of US$ 6.2 million incurred from the sales transaction. 18

View entire presentation